- A new study demonstrated that TRC101, a hydrochloric acid binder for the treatment of metabolic acidosis associated with chronic kidney disease, provided a rapid and sustained average increase in serum bicarbonate.
- All adverse effects were mild or moderate.
Metabolic acidosis—when too much acid accumulates in the body—is common in advanced stages of chronic kidney disease.
Newswise — Washington, DC (November 4, 2017) — Patients with chronic kidney disease (CKD) often develop a condition called metabolic acidosis, which is characterized by an imbalance in acid production relative to excretion. A new study appearing in an upcoming issue of the Clinical Journal of the American Society of Nephrology (CJASN) points to a novel treatment for metabolic acidosis that may be a safe and effective alternative to current therapies.
In patients with CKD, metabolic acidosis accelerates the progression of kidney disease toward kidney failure, increases muscle breakdown, worsens bone disease that accompanies kidney failure, and can increase the risk of early death. Metabolic acidosis is diagnosed by a lower than normal serum bicarbonate concentration and treatment often involves alkali supplementation with oral sodium bicarbonate; however, this treatment often requires ingesting large amounts of sodium that may worsen hypertension and fluid overload and may lead to worsening of edema and congestive heart failure in CKD patients with these common comorbidities. Other alkali compositions such as sodium citrate, potassium bicarbonate, and calcium carbonate have also been suggested, but they deliver significant amounts of sodium, potassium, or calcium to the patient.
In a study sponsored by the manufacturer of the drug, Tricida Inc., David Bushinsky, MD (University of Rochester School of Medicine) and his colleagues tested a novel approach to treating metabolic acidosis: oral administration of a non-absorbed polymer called TRC101 that binds to and eliminates acid from the gastrointestinal tract and thereby increases serum bicarbonate. “In contrast to sodium bicarbonate and other compositions that neutralize acid while also delivering sodium or other counterions, TRC101 was designed to selectively bind hydrochloric acid in the gastrointestinal tract and excrete the bound hydrochloric acid along with the feces without delivering any counterion,” explained Dr. Bushinsky.
In their first-in-human trial, the researchers randomized 135 patients with CKD and metabolic acidosis who were on a controlled diet to 14 days with placebo or 1 of 4 TRC101 dosing regimens (1.5 g, 3 g, or 4.5 g twice daily; 6 g once daily). After treatment, patients were discharged and followed for 7-14 days.
All TRC101 regimens increased serum bicarbonate from baseline to the end of treatment in a statistically significant and clinically meaningful manner, with most of the patients on TRC101 seeing greater than 3 mEq/L increases from baseline within two weeks. Further, all TRC101 treatment groups showed a significant increase in serum bicarbonate within 72 hours of the first dose. Among patients taking TRC101, serum bicarbonate was normalized at the end of treatment in 35% of patients and increased by at least 4 mEq/L in 39% of patients. After discontinuation of TRC101, serum bicarbonate decreased nearly to baseline levels within 2 weeks. All adverse events were mild or moderate, with gastrointestinal events most common. Importantly, serum electrolytes other than serum bicarbonate (such as sodium, potassium, and calcium) did not change during treatment with TRC101, and all patients completed the study.
“This study demonstrated that TRC101 was well-tolerated in CKD patients with metabolic acidosis, and treatment with TRC101 led to a rapid and sustained mean increase in serum bicarbonate,” said Dr. Bushinsky. “If longer-term studies support these initial results, TRC101, a novel, counterion-free, non-absorbed polymer, may be an important new therapeutic approach for the treatment of chronic metabolic acidosis in CKD patients.”
In an accompanying editorial, Denver Brown, MD and Michal Melamed, MD, MHS (Albert Einstein College of Medicine/Montefiore Medical Center) noted that additional studies should also include more diverse patients, including racial/ethnic minorities, and those with higher blood pressure and glucose levels than in the current study. “Hopefully the introduction of TRC101 will lead to continued interest in understanding how and why nephrologists should treat metabolic acidosis in CKD,” they wrote.
Study co-authors include Thomas Hostetter, MD, Gerrit Klaerner, PhD, Yuri Stasiv, PhD,
Claire Lockey, BA, Sarah McNulty, BS, Angela Lee, MS, Dawn Parsell, PhD, Vandana Mathur, MD, Elizabeth Li, MS, Jerry Buysse, PhD, and Robert Alpern, MD.
Disclosures: Drs. Bushinsky, Hostetter, and Alpern are consultants for Tricida, Inc. (South San Francisco, CA), and Dr. Alpern is also a member of Tricida’s Board of Directors. Drs. Mather, Parsell and Ms. Li are clinical, regulatory and biostatistics contractors and consultants, respectively, for Tricida, Inc. Authors Klaerner, Stasiv, Lockey, McNulty, Lee and Buysse are employees of Tricida, Inc.
The article, entitled “Randomized Controlled Trial of TRC101 to Increase Serum Bicarbonate in Chronic Kidney Disease Patients,” will appear online at http://cjasn.asnjournals.org/ on November 4, 2017, doi: 10.2215/CJN.07300717.
The editorial, entitled “New Frontiers in Treating Uremic Metabolic Acidosis,” will appear online at http://cjasn.asnjournals.org/ on November 4, 2017.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 17,000 members representing 112 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #
MEDIA CONTACTRegister for reporter access to contact details
Clinical Journal of the American Society of Nephrology